Paijia Medical: It is expected that the revenue in 2025 will be about 7 to 7.2 billion yuan, with a year-on-year growth of about 13.7-17.0%.

Peijia Medical announced that it expects its revenue to reach approximately 7-7.2 billion RMB in 2025, with a year-on-year growth of about 13.7-17.0%. The sustained revenue growth of the group is mainly attributed to the strong performance of all three product lines in the neurointervention business, as well as the continuous expansion of market share in the Chinese transcatheter aortic valve replacement market, driven primarily by the successful launch of the high-end TaurusMax 3D adjustable curve TAVR system.